08:05 AM EST, 12/04/2024 (MT Newswires) -- (Updates with additional details in the third, fourth and fifth paragraphs and latest stock movement in the sixth paragraph.)

Eli Lilly ( LLY ) said Wednesday its Surmount-5 phase 3b clinical study showed its Zepbound provided a 47% "greater relative weight loss" in comparison to Novo Nordisk's ( NVO ) Wegovy.

Zepbound resulted in a "superior" weight reduction of 20.2% against Wegovy's 13.7%, the company added.

Participants using Zepbound lost 50.3 pounds in weight while those using Wegovy lost 33.1 pounds, Lilly said.

At 72 weeks, Zepbound defeated Wegovy on both the primary endpoint and all five secondary endpoints in the trial, according to Lilly.

Additionally, Eli Lilly ( LLY ) said in one of the secondary endpoints, almost 32% of participants taking Zepbound reported at least a 25% loss in body weight as compared to 16% of those consuming Wegovy. The most common adverse reactions seen in the trial for both Zepbound and Wegovy were gastrointestinal-related and were "generally mild to moderate in severity," the company said.

Eli Lilly's ( LLY ) stock rose 1.1% in recent Wednesday premarket activity, while Novo Nordisk's ( NVO ) shares were down 0.02%.